Drug
Vigamox
Vigamox is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Phase Distribution
Ph phase_2
2
40%
Ph phase_4
3
60%
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 4Post-market surveillance
3(60.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (40.0%)
Phase 43 (60.0%)
Trials by Status
completed480%
withdrawn120%
Recent Activity
0 active trials
Showing 5 of 5
withdrawnphase_2
Vigamox Treatment for Ocular Graft-Versus-Host Disease
NCT04204122
completedphase_4
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
NCT00690313
completedphase_2
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
NCT02980523
completedphase_4
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
NCT00312338
completedphase_4
2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery
NCT01455233
Clinical Trials (5)
Showing 5 of 5 trials
NCT04204122Phase 2
Vigamox Treatment for Ocular Graft-Versus-Host Disease
NCT00690313Phase 4
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
NCT02980523Phase 2
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
NCT00312338Phase 4
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
NCT01455233Phase 4
2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5